GNRH1 and prostate carcinoma: Patients with prostate cancer in an advanced stage or with recurrent prostate cancer at any stage benefit from ADT with gonadotropin-releasing hormone (GnRH) analogues (GnRH agonists or antagonists), which lower androgen levels to castration levels [21, 22].